Baltimore, MDNCT06435000Now EnrollingIRB Ready

Stargardt Clinical Trial in Baltimore, MD

Access cutting-edge stargardt treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Splice Bio

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access stargardt specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stargardt treatment provided free

Apply for This Baltimore Location

Check if you qualify for this stargardt clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Stargardt Study in Baltimore

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

Sponsor: Splice Bio

Who Can Participate

Inclusion Criteria

Provide written consent
Are male or female aged 12-65 years old
Have a diagnosis of STGD1 caused by bi-allelic likely pathogenic or pathogenic variants in the ABCA4 gene confirmed genotypically by an accredited genotyping laboratory
Have a history of STGD1 progression within the last 2 years, in the opinion of the investigator.
Eligible eye(s) must have:
BCVA of between 24-88 ETDRS letters, inclusive (20/20 - 20/320 Snellen equivalent, 0.0-1.2 logMAR) at the Screening Visit.
Clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease.
Fundus autofluorescence (FAF) measurement of definitely decreased autofluorescence (DDAF) as measured by the Central Reading Center (CRC).
Total lesion must be imaged in its entirety.
All total lesion borders must be ≥300 microns from all image edges.
Eligible eye(s) must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging.

Exclusion Criteria

Are an immediate family member (e.g., child, sibling) of the Sponsor or study site personnel.
Have any concurrent ocular disease that would affect study procedures or outcomes (e.g., cataracts; subjects can be enrolled 90 days after successful cataract surgery) in eligible eyes.
Have two likely pathogenic or pathogenic variants (not STGD1) in autosomal recessive inherited retinal dystrophy (IRD) genes or a single likely pathogenic or pathogenic variant in autosomal dominant or X-linked IRD genes.
Have had any intraocular surgery or thermal laser within 90 days of study entry or any prior thermal laser in the macular region within the eligible eye(s).
Have any major surgical procedure within 30 days of the Screening Visit or planned or anticipated major surgery during the study period.
Are unwilling to stop taking the following products at Screening and throughout the study:
Supplements containing vitamin A or beta-carotene, liver-based products.
Prescription oral retinoids.
Have actively participated in an investigational therapy study or have received any investigational therapy within 90 days of the Screening Visit or 5 half-lives, whichever is longer. Note: any ophthalmic history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or intravitreal or sub-retinal injections exclude the subject from study participation.
Have known serious allergies to the fluorescein dye that might be used to measure intraocular pressure (IOP), ocular dilating drops, topical ocular anesthetic, or any history of anaphylaxis reaction.
Have a history of amblyopia in the eligible eye(s).
Have any significant ocular or non-ocular disease/disorder (or medication and/or laboratory test abnormalities) which, in the opinion of the investigator and with concurrence of the Medical Monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or affect the subject's ability to participate in the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT06435000) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stargardt Treatment Options in Baltimore, MD

If you're searching for stargardt treatment options in Baltimore, MD, this clinical trial (NCT06435000) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stargardt specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stargardt clinical trials near you to find additional studies recruiting in your area.

More Geographic Atrophy Trials in Baltimore, MD

See all geographic atrophy clinical trials recruiting in Baltimore — not just this study.

Browse Geographic Atrophy Trials in Baltimore →

Browse More Trials by Condition

Geographic Atrophy TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD